

**EFFECT OF DEHYDROEPIANDROSTERONE ON EXPRESSION OF BMP2, SPARC AND RUNX2 IN HUMAN BONE MARROW MESENCHYMAL STEM CELLS****EFFECTO DE LA DEHIDROEPIANDROSTERONA SOBRE LA EXPRESIÓN DE BMP2, SPARC Y RUNX2 EN CÉLULAS TRONCALES MESENQUIMALES DE MÉDULA ÓSEA HUMANA**

L.F. Acevedo-Olvera, H. Diaz-Garcia, O. Rodríguez-Cortes, R.R. Campos-Rodríguez, J. Cáceres-Cortes, J.M. Araujo-Álvarez, A. Parra-Barrera*, G. Gutiérrez-Iglesias

Departamento de Posgrado. Escuela Superior de Medicina, Instituto Politécnico Nacional, Distrito Federal, CP 11340, México

Received November 12, 2014; Accepted January 4, 2016

Abstract

Osteoporosis, characterized by diminished bone mineral density (BMD) and augmented susceptibility to fractures, is tied to a low level of the suprarenal steroid called dehydroepiandrosterone (DHEA). When administrated in hormonal replacement therapy, DHEA improves BMD. Although there are various physical and drug treatments to prevent bone loss, the results have generally been poor. For this reason, cellular therapy based on the application of mesenchymal stem cells has emerged as an attractive alternative. In this study the effect of DHEA on osteogenic gene expression of human bone marrow mesenchymal stem cells (hBM-MSCs). Cell population obtained was characterized as having fibroblastoid morphology and the expression of antigens positive for CD90, CD73, CD13 and CD105. The plasticity of hBM-MSCs was evident and corroborated by adipocytes and osteoblast differentiation. DHEA concentration used in all experiments were 1, 10 and 100 μM during seven days and after the expression of mRNA BMP2, RUNX2 and SPARC (the main involved genes on osteogenic differentiation) was evaluated. Results showed that all DHEA concentration induced high expression on mRNA of BMP2, RUNX2 and SPARC. However, DHEA at 1 μM induced a higher accumulation of extracellular Ca^{++} which it's a characteristic for bone formation. This work confirms that DHEA could be considered an alternative in the treatment of bone diseases.

Keywords: mesenchymal stem cells, dehydroepiandrosterone, osteogenic differentiation.

Resumen

La osteoporosis se distingue por la disminución de la densidad mineral ósea responsable de susceptibilidad a fracturas. Esta característica se acentúa cuando disminuye la producción de la dehidroepiandrosterona (DHEA). La DHEA se utiliza en terapias de remplazo hormonal y mejora la densidad ósea. Los actuales tratamientos físicos y químicos para prevenir la pérdida ósea, generalmente tienen pobres beneficios y por esta razón, la terapia celular basada en la aplicación de Células Troncales Mesenquimales representa una alternativa. En este trabajo se demostró el efecto de la DHEA sobre la expresión de genes óseos en Células Troncales Mesenquimales derivadas de Médula Ósea humana (hBM-MSC). La población celular obtenida presentó tanto morfología fibroblastoide como expresión de antígenos de superficie positivos CD90, CD73, CD13 y CD105. La plasticidad celular fue evidente por la diferenciación de hBM-MSC hacia osteoblastos y adipocitos. Las concentraciones utilizadas de DHEA fueron 1, 10 y 100 μM por 7 días, después se evaluó la expresión del mRNA para los principales genes involucrados en la diferenciación osteogénica como BMP2, RUNX2 y SPARC. Los resultados mostraron una sobreexpresión de BMP2, RUNX2 y SPARC inducidos por DHEA a todas las concentraciones, sin embargo, a 1 μM se indujo la mayor acumulación de Ca^{++} extracelular, evento que evidencia la formación de hueso. Este trabajo confirma que la DHEA puede ser considerada como una alternativa en el tratamiento de enfermedades con pérdida ósea.

Palabras clave: células troncales mesenquimales, dehidroepiandrosterona, diferenciación osteogénica.

1 Introduction

Osteoporosis, characterized by low bone mineral density (BMD) that causes susceptibility to fracture, is related to a decrease in the production of

dehydroepiandrosterone (DHEA), an adrenal steroid (Cormier *et al.*, 2001; Zhang *et al.*, 2014) and cholesterol derivative (Baeza-Jiménez *et al.*, 2014). In humans, DHEA is synthesized in the adrenal cortex, gonads, brain and gastrointestinal tract, and may be

* Corresponding author. E-mail: iglesiasgg@yahoo.com and alberto.parrab1@hotmail.com

produced by other organs like heart (Nakamura *et al.*, 2004). DHEA affects the endocrine, immune and metabolic systems (Bellino *et al.*, 1995) due to its antioxidant effect as well as some natural molecules called polyphenols to promote health benefits (Sánchez-Rangel *et al.*, 2013). It has been reported that DHEA has an anti-inflammatory role in endothelial cell veins (Gutiérrez *et al.*, 2007).

In humans, DHEA levels decline with aging (Nestler *et al.*, 1988; Macewen and Kurzman, 1991). Low serum levels of DHEA are associated with an increased risk of age-related chronic diseases like insulin resistance (Schriock *et al.*, 1988), obesity (Nestler *et al.*, 1988), cardiovascular disease (Macewen and Kurzman, 1991), cancer (Barrett-Connor *et al.*, 1986), immunodeficiency (Schwartz *et al.*, 1986), and psychosocial problems such as depression and/or a general deterioration in the sense of well-being (Casson *et al.*, 1993).

Regenerative medicine is currently looking for new strategies to improve the cell therapies for osteoporosis by using mesenchymal stem cells (MSCs) for bone repair. MSCs have been isolated from different tissues, those from human bone marrow (hBM) being the easiest to harvest and expand *in vitro*. In this context, human bone marrow is the niche of hematopoietic (Andrade-Zaldívar *et al.*, 2014) and mesenchymal stem cells, the latter of which are multipotent progenitor cells that can differentiate into osteoblasts, adipocytes, chondrocytes, tenocytes, skeletal myocytes and neurons (Rodríguez-Pardo *et al.*, 2010; Wang *et al.*, 2012), which is very attractive for cell therapy. There is some evidence that different concentrations of DHEA can induce osteogenic differentiation of hBM-MSCs (Kaivosoja *et al.*, 2010). When administrated in hormonal replacement therapy, DHEA improves BMD (Morales *et al.*, 1998; Baulieu *et al.*, 2000), but how DHEA do it, remains poorly studied. The aim of the present study was to determine the effects of DHEA on osteogenic gene expression in mesenchymal stem cells from the bone marrow of healthy patients. The results support that DHEA is suitable for use as a co-adjuvant in the strategies for alternative treatments in bone repair.

2 Experimental details

2.1 Materials and methods

2.1.1 Human bone marrow mesenchymal stem cell isolation

Three samples of human bone marrow (hBMs) were donated by the orthopedic service of the Hospital General de Puebla SSA. hBMs were diluted 1:2 in Hanks balanced salt solution (HBSS; Gibco). A mononuclear pellet (MNCs) was recovered by density-gradient centrifugation (Lymphoprep 1.077 g/mL) and cultured in 25 cm² flasks (BD Falcon, Becton Dickinson) at a concentration of 30×10^6 nucleated cells in 5 ml of Dulbecco's modified Eagle's and F12 medium (DMEM), glutamax 1X, 15% fetal bovine serum, and antibiotic-antimycotic 1X (Gibco, USA). Cultures were maintained at 37°C in a 5% CO₂ atmosphere and after 72 hours non-adherent cells were removed. When 70%-80% of adherent cells reached confluence, they were trypsinized (0.05% trypsin/EDTA) at 37°C for 5 to 10 minutes, then harvested and expanded in a Petri dish 100 x 20 mm (Corning, USA). A homogeneous cell population was obtained after 2 to 3 weeks of culture. Cell cultures at passage 3 were used for all experiments.

2.1.2 Monoclonal antibodies and immune phenotyping

Monoclonal antibodies against human CD45 conjugated to fluorescein isothiocyanate (FITC), CD34 conjugated to FITC, CD13 conjugated to phycoerythrin (PE), CD105 conjugated to FITC, CD73 conjugated to PE, and CD90 conjugated to FITC were purchased from Biolegend (England). Monoclonal antibodies against human CD14 conjugated to PE as well as HLA-DR conjugated to FITC were purchased from Santa Cruz, CA, USA. Cells were washed twice with ice-cold phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin (BSA), followed by incubation with saturated concentrations of the appropriate antibodies for 20 minutes at 4°C. Afterwards, cells were washed twice in ice-cold PBS/1% BSA and fixed with 1% paraformaldehyde in PBS. Samples were acquired through FacScalibur (Becton Dickinson) and were analyzed by the Cell Quest software program.

2.1.3 In vitro differentiation assays

hBM-MSCs were plated at 2,000 cells/mL and then the differentiation medium was added. To

induce osteogenic differentiation, the cells were cultured for 21 days in the presence of StemPro osteocyte/chondrocyte differentiation basal medium with StemPro osteogenesis supplement or StemPro adipogenesis differentiation basal medium with adipogenesis StemPro supplement (Gibco, USA). Then cells were fixed with formol at 10% and were stained with specific dyes (see the following section).

2.1.4 Evaluation of osteogenic and adipogenic differentiation potential

Osteoblasts were identified by staining with Alizarin Red S (Sigma). Briefly, the hBM-MSC cultured at 21 days with StemPro osteogenesis medium and were washed with PBS and incubated with 2% Alizarin Red S solution (pH of 5.5 with 0.5% NH₄OH, and that identifying deposits Ca⁺⁺ extracellular) for 5 min before being observed in an optical microscope (Leica, Germany) at 10X and 40X objective with integrate digital camera DP24 U/S 3016433.

For confirm that hBM-MSC differentiate into osteoblast was performed semi-quantification assays. After hBM-MSC were Alizarin red staining they were PBS washed and 1 ml phosphate buffer (8 mM Na₂HPO₄ + 1.5 mM KH₂PO₄) containing 10% cetylpyridinium chloride (Sigma) was added and this was incubated for 10 min to dissolve the alizarin red dye. Later this supernatant was measured spectrophotometrically at 550 nm with a microplate reader (BioRad, USA).

Adipocytes were identified by Oil Red staining (Sigma). Briefly, the hBM-MSC were cultured with StemPro adipogenesis medium for 21 days and were staining with Oil Red (for identifying intracellular lipid vesicles, Sigma) for 15 min at room temperature. Afterward, cells were washed completely with isopropanol (Sigma) at 60% and then observed in an optical microscope (Leica, Germany) at 10 and 40X objective with integrate digital camera DP24 U/S 3016433.

2.1.5 Statistic analysis

Values are expressed as mean ± standard deviation. Statistics analyses were performed with students's t test and one way ANOVA by Microsoft Excel. A significant difference was considered at $p \leq 0.05$.

2.1.6 Genetic expression and reverse transcription polymerase chain reaction

Total RNA was isolated from the hBM-MSC using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. Afterwards, the total RNA sample was used for synthesis of cDNA, according to the manufacturer's instructions (Illumina, USA). Primers were designed by using the Oligo Explorer 1.0 program with the following sequences: forward-GAPDH (5'-TCAACGACCACTTTGTCAAG-3') and reverse-GAPDH (5'-ACTGTGAGGAGGGGAGATTC-3'), forward-SPARC (5'-CAGAGGAAACCGAAGAGGAG-3') and reverse-SPARC (5'-GCAAAGAAGTGGCAGGAAG-3'), forward-RUNX2 (5'-AGTGCGGTGCAAACCTTCTC-3') and reverse-RUNX2 (5'-CTGCTTGACGCCTTAAATGA-3'), forward-BMP-2 (5'-GGACGCTCTTTCATGGAC-3') and reverse-BMP-2 (5'-GGTGGTCTCTGTTTCAGG-3'). Gene sequences were obtained from the database (<http://www.ncbi.nlm.nih.gov/pubmed>) and specificity was analyzed by BLAST. To carry out RT-PCR endpoint for GAPDH, BMP2, SPARC and RUNX2 genes, an Eppendorf Mastercycler Thermal Cycler[®] was used for PCR amplification: denaturation at 94 °C for 1 min; alignment at 58-60 °C for 1 min; extension at 72 °C for 30 sec, 30-35 cycles. The reaction products were resolved by electrophoresis on 2% agarose gel dissolved in TAE buffer solution (40 mM Tris-acetate and 1mM EDTA) and visualized with ethidium bromide staining in a documentation system GEL DOC XR (BioRad).

3 Results and discussion

3.1 Cell morphology and immunophenotyping

hBM-MSCs are a morphologically distinct population in primary culture. Although the cell population tends to become visually more homogenous with subsequent *in vitro* expansion (Nestler *et al.*, 1988; Schriock *et al.*, 1988; Macewen and Kurzman, 1991), the cells must be characterized under the protocol of the International Society for Cell Therapy (ISCT). hBM-MSCs grew as a monolayer of plane and larged cells, and in confluency they assumed a more spindle-shaped homogenous population with a fibroblast-like morphology at pass three (Fig. 1A). To evaluate plasticity, hBM-MSCs were differentiated into osteoblasts and adipocytes for 21 days. Lipid vesicles (droplets) were found in mature and partial-

mature adipocytes cells-hBM-MSC differentiated (Fig. 1B-C) and extracellular Ca^{++} deposits were identified in osteoblasts-hBM-MSCs differentiated (Fig. 1D-E).

Another standard proposed by ISCT is a general panel of positive and negative cell surface markers that now are commonly used to characterize the immunophenotype of MSCs (Rodríguez-Pardo *et al.*, 2010). A wide panel of cell-surface antigens was measured by flow cytometry analysis. hBM-MSCs had diminished expression of hematopoietic markers: CD14 (1.23%), CD34 (1.47%), CD45 (1.76%) and HLA-DR (2.05%). However, they were positive for CD13 (54.1%), CD73 (47.91%), CD90 (51.75%) and CD105 (15.34%) (Fig. 2). These results indicate that population of hBM-MSCs was heterogeneous and poorly enriched, but they accomplished the ISCT standards in accordance to reports in literature. (Phinney *et al.*, 1999; Gnecci and Melo, 2009).

hBM-MSC used in this study showed low percentages of membrane markers, but this may be due to many factors, for example, Flores *et al.* (2006), mentioned that depending on the methodology

used this may influence to obtain a population of hBM-MSC either pure or homogeneous. Using ficoll-hypaque cell population results less pure and more heterogeneous, and when other sophisticated methodology is used or a combination of them, like works by Neagu *et al.*, (2005) and Huang *et al.* (2015), who used separation method by ficoll-hypaque and then recovering cells were sorted using fluorochrome labeled antibodies, the population isolated resulting was pure and homogeneous. However, that results were on passage 25, when the population is fairly homogeneous and 99% CD105 positive. The above mentioned is consistent with observations by Mafi *et al.*, (2011), where variability in expression of membrane markers may be due to the state of cell proliferation and culture at the time to be evaluated. Results shown here were carried out in population of hBM-MSC at passage three and only were purified using ficoll-hypaque gradient. It would be interesting that cells used in this work could be evaluated in higher passages and for other membrane markers presents also in adherent cells from bone marrow, such as endothelial and/or epithelial cells.




Fig. 1. Cell cultures of hBM-MSCs and characterization of cell plasticity *in vitro*. A) hBM-MSCs in culture shows large, flat cells, spindle-shaped and fibroblastic morphology at pass three. B-C) Mature (black arrows) and partial-mature adipocytes (blue arrows) were identified by Oil red stainings for lipid vesicles in hBM-MSCs differentiated at 21 days. D-E) Osteoblast were identified by Alizarin red stainings for Ca^{++} deposits in hBM-MSCs differentiated at 21 days (arrows). Microscopy Ligth 10X and 40X.




Fig. 2. Flow cytometric analysis of membrane markers on hBM-MSCs at passage three. The hBM-MSC demonstrate that were negative for hematopoietic cell markers CD14, CD34, CD45 and HLA-DR and CD13, CD73, CD90 and CD105 were still expressed. Antibody anti-IgG1 were used as control (CAF). FITC, fluorescein isothiocyanate; PE, phycoerythrin.

3.2 Gene expression in hBM-MSC stimulated with DHEA

GAPDH (housekeeping) remained constant under all conditions, while the RUNX2 and SPARC mRNA expression had basal levels in the control cells and higher expression with DHEA treatment at each of concentrations. (Fig. 3). Hence, it is possible that the role of RUNX2 and SPARK genes are not

directly related to osteogenic differentiation induced by DHEA. Niu *et al.*, (2012) described the basal mRNA expression of RUNX2 in WRO and TCP-1 cells and showed that this is influenced by fetal bovine serum (FBS) similar to results here presented.

It is known that both gene expression and protein synthesis of osteonectin (SPARC) and RUNX2 are associated in a closely and dependent way (Ducy *et al.*, 1997; Jang *et al.*, 2012).




Fig. 3. Differentiation of hBM-MSC to osteoblastic cells for with DHEA at 7 days. The hBM-MSC were cultured in absence (-) or the presence (+) DHEA at 1, 10 and 100 μM or osteogenic medium (osteo) during 7 days and afterwards RT-PCR was carried out. The expression of GAPDH (endogen control), RUNX2, SPARC and BMP2 were observed in a 2% agarose gel. The DHEA induced the expression of BMP2 at 1, 10 and 100 μM on hBM-MSC similar to osteogenic medium.

Also it has been reported recently in hBM-MSC a basal expression of SPARC (Karaoz *et al.*, 2009), which is in consistent with the observed in hBM-MSC with or without DHEA treatment (Fig. 3). In contrast with the observed for SPARC or RUNX2, BMP2 mRNA was not expressed in cells without DHEA stimuli (negative control), but it was presented in cells cultivated with osteogenic medium (positive control) as well in DHEA at 1, 10 and 100 μM (Fig. 3). The gene BMP2 is considered one of the most important in relation to the osteogenic differentiation of MSCs (Davis *et al.*, 2011; Quing *et al.*, 2012; Wang *et al.*, 1990; Wozney *et al.*, 1988) because it's expression orchestrate other osteogenic genes like RUNX2 and SPARC (Jang *et al.*, 2012). In this work RUNX2 expression was observed in all hBM-MSC, possibly because extra to be a gene involved in the osteogenesis process, it could participate in other functions, for example on cell cycle (Ko *et al.*, 2011; Komori, 2010; Chung *et al.*, 2005). Here, results showed in cultures treated with DHEA that BMP2 gene expression was constant (Fig. 3) and similar to observed with osteogenic medium treatment.

3.3 Extracellular calcium resulting from DHEA-induced osteoblastic differentiation

To confirm that DHEA promotes differentiation from hBM-MSC to osteoblasts, hBM-MSC were cultured in presence of osteogenic medium (positive control) or DHEA (1, 10 and 100 μM). The concentration of extracellular Ca^{++} was much higher in hBM-




Fig. 4. Semi-quantification of extracellular Ca^{++} assessed by Alizarin red solubilized in hBM-MSC differentiated on osteoblast with DHEA. hBM-MSC were stimulated seven days with osteogenic medium or DHEA at 1, 10 and 100 μM and it is confirmed that DHEA at 1 μM induced the differentiation to osteoblasts. Significant differences were from osteogenic medium (control) are indicated as follows: * ($p=0.02$), ** ($p=0.01$), *** ($p=0.009$) by the Student's t-test and * ($p=0.05$) by Anova.

MSCs exposed to DHEA at 1 μM than hBM-MSCs in other culture media (osteogenic medium or medium with DHEA at 10 or 100 μM ; Fig. 4). These results are similar to founded by Kaivosoja *et al.*, (2012), where DHEA at 100 μM induces the synthesis of alkaline phosphatase, osteopontin, osteocalcin and RUNX2. Malik *et al.*, (2010) investigated in hBM-MSC stimulated with 0.1, 1 and 10 μM of β -AET, one metabolite of DHEA, that after 15 days of stimuli the osteoblastic differentiation occurred, which it was corroborated by osteopontin positive cells.

Results showed statistical significance between hBM-MSCs cultured with osteogenic medium and 1, 10 and 100 μM of DHEA stimuli analyzed by students's t test ($p = 0.02, 0.01, 0.009$ respectively) while data analysis by ANOVA indicates just a significant difference between hBM-MSC osteogenic medium and 1 and 10 μM of DHEA stimuli ($p = 0.05$).

Concentrations on serum DHEA varies throughout of life reaching a peak at around 10 μM in blood (Jean-Pierre *et al.*, 2013). In this study, physiologic concentrations of DHEA (1 and 10 μM) cells showed an osteogenic differentiation, although the effect is well observed at pharmacological concentrations (100 μM) in comparison to untreated cells. Clinical studies in old subjects (where DHEA keep diminished), physiological DHEA concentrations on blood could be recovered with doses of 50-100 mg of DHEA per day,




Fig. 5. General proposed mechanism for expression of BMP2 induced by DHEA, (see the text). MAPK (Mitogen-Activated- Protein-kinase); ERK1/2 (Extracellularly-Responsive-Kinase 1/2); PKA (Protein Kinase A); ELK1 (Ets-like protein-1); CREB (cyclic AMP response element binding protein); and BMP2 (Bone Morphogenetic Protein 2).

and the treatment does not present collateral effects (Legrain and Girard, 2003).

These results confirm that DHEA is a good inducer of osteogenic differentiation, and that it could possibly be used alone or as a co-adjuvant in long-term alternative treatments for bone repair. There are some mechanisms which propose how DHEA acts. The figure 5 shows the proposed signaling for expression of BMP2 induced by DHEA (confirmed in this work), together with information founded in literature and sustained by others authors. DHEA can bind to G-coupled protein receptor [1] (Siddappa *et al.*, 2008) and through of a complex process relationship to G-protein it's activated MAPK signaling pathway [2] (Gavi *et al.*, 2006; Wang *et al.*, 2007). Downstream,

some protein kinases like ERK1/2 [3] (Wang *et al.*, 2007) and PKA [4] (Siddappa *et al.*, 2007), could phosphorylate transcription factors as ELK1 [5] (Li *et al.*, 2013) and CREB [6] (Siddappa *et al.*, 2008). In response of this, the expression of BMP2 gene increases [7] (Ionescu *et al.*, 2004; Siddappa *et al.*, 2008), and as a consequence BMP2 is synthesized in cytoplasm. Later on the cell outside, extracellular mineralization [8] (Ronchetti *et al.*, 2013) and bone formation occur [9] (Baulieu *et al.*, 2000; Arlt *et al.*, 2001; Kahn *et al.*, 2002). (Fig. 5).

Conclusions

The results of the present cultures with hBM-MSCs are indicative of molecular mechanisms of osteogenic differentiation, according to the standards of International Society for Cellular Therapy (ISCT). DHEA induced osteogenic differentiation and the principal gene responsible for this result is BMP2. DHEA at 1 and 10 μ M physiological doses was found herein to induce high concentrations of extracellular Ca⁺⁺ as a result of the overexpression of RUNX2, SPARC and BMP2 osteogenic genes, probably by a signaling that involved the molecules and transcription factors from binding DHEA to known receptor. Further studies are necessary to identify specific mechanisms that are involved when using DHEA as a dietary supplement for patients with osteoporosis. At the moment, for these patients, there has been a documented improvement in BMD by induction of osteogenic genes with DHEA treatment.

Acknowledgments

We thank Hospital General de Puebla "Dr. Eduardo Vázquez Navarro" and the Centro Nacional de la Transfusión Sanguínea (Mexico City). Acevedo-Olvera L.F. and Diaz-Garcia H., PhD students in the Escuela Superior de Medicina, Instituto Politécnico Nacional, are grateful for grants received from Consejo Nacional de Ciencia y Tecnología (CONACyT: scholarship # 273099 and 263830, respectively). This work was supported by the BEIFI and SIP (project # 20131092).

Abbreviations

DHEA	dehydroepiandrosterone
BMD	bone mineral density
MSCs	mesenchymal stem cells

hBM	human bone marrow
BMs	Bone Marrow samples
HBSS	Hanks balanced salt solution
MNCs	Mononuclear pellet
FITC	fluorescein isothiocyanate
O.D.	optical density
GAPDH	glyceraldehyde 3-phosphate dehydrogenase
RUNX2	Runt-related transcription factor 2
SPARC	Scalable processor architecture
BMP2	Bone morphogenetic protein 2
ISCT	International Society for Cellular Therapy

References

- Andrade-Zaldívar H., Kalixto-Sánchez M.A., Barba de la Rosa A.P., De León-Rodríguez A. (2014). Expansion of CD34⁺ Human Hematopoietic Cells from Umbilical Cord Blood using roller bottles. *Revista Mexicana de Ingeniería Química* 13, 379-385.
- Arlt W., Callies F., Koehler I., van Vlijmen J.C., Fassnacht M., Strasburger C.J., Seibel M.J., Huebler D., Ernst M., Oettel M., Reincke M., Schulte H.M., Allolio B. (2001) Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. *The Journal of Clinical Endocrinology & Metabolism* 86, 4686-92.
- Baeza-Jiménez R., López-Martínez L.X., García H.S. (2014). Biocatalytic modification of food lipids: reactions and applications. *Revista Mexicana de Ingeniería Química* 13, 29-47.
- Barrett-Connor E., Khaw K.T., Yen S. (1986). A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. *New England Journal of Medicine* 315, 1519-1524.
- Baulieu E.E., Thomas G., Legrain S., et al., (2000). Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of DHEA Age study to a sociobiomedical issue. *Proceeding of the National Academy of Sciences USA* 97, 4279-84.
- Bellino F.L., Daynes R.A., Hornsby P.J., Lavrin D.H., Nestler, J.E. (1995). Dehydroepiandrosterone (DHEA) and Aging. *NY Academy of Science*.
- Casson P.R., Andersen R.N., Herrod H.G., Stentz F.B., Straughn A.B., Abraham G.E., Buster J.E. (1993). Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. *American Journal of Obstetrics and Gynecology* 169, 1536-1539.
- Chung HC., Mei LH., Je KC., Shao HH., Gwo JW. (2005). Green tea catechin enhances osteogenesis in a bone marrow mesenchymal stem cell line. *Osteoporosis International* 16, 2039-2045.
- Cormier C., Souberbielle J.C., Kahan A. (2001). DHEA in bone and joint diseases. *Joint Bone Spine* 68, 588-94.
- Davis H.E., Case E.M., Miller S.L., Genetos D.C., Leach J.K. (2011). Osteogenic Response to BMP-2 of hMSCs Grown on Apatite-Coated Scaffolds. *Biotechnology and Bioengineering* 108, 2727-35. doi: 10.1002/bit.23227.
- Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. (1997). Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. *Cell* 89, 747-54.
- Flores-Figueroa E, Montesinos J.J, Mayani H. (2006). Células Troncales Mesenquimales: historia biología y aplicación clínica. *Revista de Investigación Clínica* 58, 498-511.
- Gavi S., Shumay E., Wang H.Y., Malbon C.C. (2006). G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. *Trends in Endocrinology Metabolism* 17, 48-54.
- Gnecchi M., Melo L.G. (2009). Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. *Methods in Molecular Biology* 482, 281-94. doi: 10.1007/978-1-59745-060-7_18.
- Gutiérrez G., Mendoza C., Zapata E., Montiel A., Reyes E., Montaña L.F., López-Marure R. (2007). Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells. *Atherosclerosis* 190, 90-99.
- Huang J., Sha H., Wang G., Bao G., Lu S., Luo Q., and Q Tan. (2015). Isolation

- and characterization of ex-vivo expanded mesenchymal stem cells obtained from a surgical patient. *Molecular Medicine Reports* 11, 1777-83.
- Hughes F.J., Turner W., Belibasakis G., Martuscelli G. (2000). Efectos de los factores de crecimiento y de las citocinas sobre la diferenciación de los osteoblastos. *Periodontology 2000 (Ed Esp)* 15, 48-72.
- Ionescu A.M., Drissi H., Schwarz E.M., Kato M., Puzas J.E., McCance D.J., Rosier R.N., Zuscik M.J., O'Keefe R.J. (2004). CREB Cooperates with BMP-stimulated Smad signaling to enhance transcription of the Smad6 promoter. *Journal of Cell Physiology* 198, 428-40.
- Jang W.G., Kim E.J., Kim D.K., Ryoo H.M., Lee K.B., Kim S.H., Choi H.S., Koh J.T. (2012). BMP2 Protein Regulates Osteocalcin Expression via Runx2-mediated Atf6 Gene Transcription. *Journal of Biological Chemistry* 287, 905-915.
- Jean-Pierre Savineau, Roger Marthan, Eric Dumas de la Roque. (2013). Role of DHEA in cardiovascular diseases. *Biochemical Pharmacology* 85, 718-726.
- Kahn A.J., Halloran B., Wolkowitz O., Brizendine L. (2002). Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. *Journal of Clinical Endocrinology Metabolism* 87, 1544-9.
- Karaoz E, Aksoy A, Ayhan S, Sariboyaci AE, Kaymaz F, Kasap M. (2009). Characterization of mesenchymal stem cells from rat bone marrow: ultrastructural properties, differentiation potential and immunophenotypic markers. *Histochemical Cell Biology* 132, 533-46.
- Kaivosoja E., Sariola V., Chen Y., Kontinen Y.T. (2012). The effect of pulsed electromagnetic fields and dehydroepiandrosterone on viability and osteoinduction of human mesenchymal stem cells. *Journal of Tissue Engineering Regenerative Medicine*. doi:10.1002/term.1612.
- Ko CH., Siu WS., Wong HL., Shum WT., Fung KP., San Lau CB., Leung PC. (2011). Pro-bone and antifat effects of green tea and its polyphenol, epigallocatechin, in rat mesenchymal stem cells *in vitro*. *Journal of Agricultural Food Chemistry Separations* 28, 9870-6.
- Komori T. (2010). Regulation of Osteoblast Differentiation by Runx2. *Advances in Experimental Medical Biology* 658, 43-49.
- Li Q.J., Yang S.H., Maeda Y., Sladek F.M., Sharrocks A.D., Martins-Green M. (2013). MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. *EMBO Journal* 22, 281-91.
- Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. (2011). Sources of adult mesenchymal stem cells applicable for musculoskeletal applications a systematic review of the literature. *Open Orthopedics Journal* 5 Suppl 2, 242-8.
- Macewen E.G. and Kurzman I.D. (1991). Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). *Journal of Nutrition* 121, s51-s55.
- Malik A.K., Khaldoyanidi S., Auci D.L., Miller S.C., Ahlem C.N., Reading C.L., Page T., Frincke J.M. (2010). 5-Androstene-3 β ,17 β -triol (β -AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis. *PLoS One* 5, e13566. doi: 10.1371/journal.pone.0013566.
- Morales AJ., Haubrich RH, Hwang JY, et al. (1998). The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. *Clinical Endocrinology* 49, 421-32.
- Nakamura S., Yoshimura M., Nakayama M., Ito T., Mizuno Y., Harada E., Sakamoto T., Saito Y., Nakao K., Yasue H., Ogawa H. (2004). Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. *Circulation* 110, 1787-1793.
- Neagu M., Suci E., Ordodi V., and V. Paunescu. (2005). Human mesenchymal stem cells as basic tolos for tissue engineering: isolation and culture. *Romanian Journal of Biophysics* 15, 29-34.

- Nestler J.E., Barlascini C.O., Clore J.N. and Blackard W.G. (1988). Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. *Journal of Clinical Endocrinology and Metabolism* 66, 57-61.
- Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, Yamane T, Katoh R. (2012). Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. *Laboratory Investigations* 92, 1181-1190.
- Phinney D.G., Kopen G., Isaacson R.L., Prockop D.J. (1999). Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. *Journal of Cell Biochemistry* 72, 570-85.
- Qing W., Guang-Xing C., Lin G., Liu Y. (2012). The Osteogenic Study of Tissue Engineering Bone with BMP2 and BMP7 Gene-Modified Rat Adipose-Derived Stem Cell. *Journal of Biomedicine and Biotechnology*, ID 410879.
- Ronchetti I., Boraldi F., Annovi G., Cianciulli P., Quaglino D. (2013). Fibroblast involvement in soft connective tissue calcification. *Frontiers in Genetics* 4, doi: 10.3389/fgene.2013.00022.
- Rodríguez-Pardo V.M., Fuentes-Lacouture M.F., Aristizabal-Castellanos J.A., Vernot J.P.H. (2010). Aislamiento y caracterización de células "stem" mesenquimales de médula ósea humana según criterios de la Sociedad Internacional de Terapia Celular. *Universitas Scientiarum* 15, 224-239.
- Sánchez-Rangel J.C., Benavides J. and Jacobo-Velázquez D.A. (2014). Abiotic stress based bioprocesses for the production of high value antioxidant phenolic compound in plants: an overview. *Revista Mexicana de Ingeniería Química* 13, 49-61.
- Schriock E.D., Buffington C.K., Hubert G.D., Kurtz B.R., Kitabchi A.E., Buster J.E., Givens J.R. (1988). Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. *Clinical Endocrinology and Metabolism* 66, 1329-1331.
- Schwartz A.G., Pashko L. and Whitcomb J.M. (1986). Inhibition of tumor development by dehydroepiandrosterone and related steroids. *Toxicologic Pathology* 14, 357-362.
- Siddappa R., Martens A., Doorn J., Leusink A., Olivo C., Licht R., van R.L., Gaspar C., Fodde R., Janssen F., van B.C., de B.J. (2008). cAMP/PKA pathway activation in human mesenchymal stem cells *in vitro* results in robust bone formation *in vivo*. *Proceedings of the National Academy of Science USA* 105, 7281-6.
- Sylvie Legrain and Laurence Girard. 2003. Pharmacology And Therapeutic Effects of Dehydroepiandrosterone In Older Subjects. *Drugs Aging*. 20 (13): 949-967.
- Wang L., Wang Y.D., Wang W.J., Zhu Y., Li D.J. (2007). Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. *Journal of Molecular Endocrinology* 38, 467-79.
- Wang L., Wang Y.D., Wang W.J., Zhu Y., Li D.J. (2007). Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. *Journal of Molecular Endocrinology* 38, 467-79.
- Wang EA., Rosen V., D'Alessandro J.S., Bauduy M., Cordes P., Harada T., Israel D.I., Hewick R.M., Kerns K.M., LaPan P., et al. (1990). Recombinant human bone morphogenetic protein induces bone formation. *Proceedings of the National Academy of Science USA*. Mar 87, 2220-4.
- Wang Y.D., Tao M.F., Cheng W.W., Liu X.H., Wan X.P., Cui K. (2012). Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway. *Chinese Medical Journal (Engl)* 125, 1230-5.
- Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang EA. (1988). Novel regulators of bone formation: molecular clones and activities. *Science* 242, 1528-34.

Zhang J., Delzell E., Curtis J.R., Hooven F., Gehlbach S.H., Anderson F.A. Jr, Saag K.G. (2014). Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass. *Osteoporosis*

International 25, 317-24.

Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M. (2012). Wnt/ β -catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. *Bone* 52, 145-56